A study in Clinical Cancer Research showed that UroCAD, a urine-based whole-genome sequencing assay, yielded high sensitivity and similar specificity in diagnosing urothelial cancer, compared with standard urine cytology. The findings suggest that UroCAD may be beneficial in patients with suspected upper urinary tract urothelial carcinoma, but more studies are still needed to assess its efficacy in disease surveillance, said researcher Chuan-Liang Xu.